Investors

  • 2021-01-18
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON AMENDED AGREEMENT WITH SPERO THERAPEUTICS
  • 2021-01-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2020
  • 2021-01-06
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY FOR METASTATIC UROTHELIAL CANCER
  • 2021-01-06
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON SUBMISSION OF NEW DRUG APPLICATION IN SINGAPORE FOR SACITUZUMAB GOVITECAN-HZIY FOR THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER
  • 2020-12-22
    CHANGE IN DIRECTORS OR OF IMPORTANT EXECUTIVE FUNCTIONS OR RESPONSIBILITIES
    APPOINTMENT OF NON-EXECUTIVE DIRECTOR
  • 2020-12-09
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON FIRST PATIENT DOSED IN PHASE 3 REGISTRATION ASIAN STUDY OF TRODELVY (SACITUZUMAB GOVITECAN) FOR HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER
  • 2020-12-04
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2020
  • 2020-12-04
    (REVISED) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED OCTOBER 31, 2020
  • 2020-12-02
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECOMMENDED BREAKTHROUGH THERAPY DESIGNATION FOR NEFECON FOR THE TREATMENT OF IGA NEPHROPATHY
  • 2020-11-10
    VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON LICENSING PARTNER CALLIDITAS THERAPEUTICS REPORTING TOPLINE RESULTS FROM PIVOTAL PHASE 3 NEFIGARD TRIAL
 Copyright Everest Medicines 2020   苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers